Research and analysis
Annex 3: Table 2
Updated 28 June 2021
Download CSV 934 Bytes
| Setting | Study Design | Comparator | Erythromycin, n*/N | Comparator, n*/N | Outcome | Study | Risk Estimate (95% Cl) | Rate per 1000 exposed to macrolide | Rate per 1000 exposed to comparator | Rate difference | Overall Bias |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UK 1990-2016 | Cohort | Penicillin | 6/162 | 398/22,544 | MCM | Fan et al 2020 | 1.83(0.83-4.04) | 36.81 | 17.65 | 19.16 | serious |
| Denmark 1997-2007 | Cohort | unexposed | 9/253 | 24/808 | MCM | Andersen et al 2013 | 1.01 (0.52-1.97) | 35.57 | 29.7 | 5.87 | serious |
| Quebec 1998-2009 | Cohort | Penicillin | 77/658 | 894/9,106 | MCM | Muanda 2017b | 1.15 (0.90-1.48) | 117.02 | 98.18 | 18.84 | serious |
| Denmark 1997-2007 | Cohort | unexposed | 1/10 | 77,513/931,103 | Miscarriage | Andersen et al 2013 | 1.66* (1.22-2.26) | 99.75 | 83.25 | 16.5 | serious |
| Quebec 1998-2009 | Case-control | Penicillin | 111/8702* | 5573/87,020 | Miscarriage | Muanda 2017a | 2.73* (2.16-3.44) | n/a | n/a | n/a | Moderate |
| Quebec 1998-2009 | Cohort | Penicillin | 12/658 | 192/9,106 | CVM | Muanda2017b | 0.82 (0.46-1.48) | 18.24 | 18.24 | -2.85 | serious |